- Comment in:
-
Lancet. 2005 Apr 2-8;365(9466):1229-30.
-
Lancet. 2005 Apr 2-8;365(9466):1230.
-
Lancet. 2005 Jan 29-Feb 4;365(9457):363-4.
Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease.
Nichols WC,
Pankratz N,
Hernandez D,
Paisán-Ruíz C,
Jain S,
Halter CA,
Michaels VE,
Reed T,
Rudolph A,
Shults CW,
Singleton A,
Foroud T;
Parkinson Study Group-PROGENI investigators.
Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA. Bill.nichols@cchmc.org
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene cause some forms of autosomal dominant Parkinson's disease. We measured the frequency of a novel mutation (Gly2019 ser) in familial Parkinson's disease by screening genomic DNA of patients and controls. Of 767 affected individuals from 358 multiplex families, 35 (5%) individuals were either heterozygous (34) or homozygous (one) for the mutation, and had typical clinical findings of idiopathic Parkinson's disease. Thus, our results suggest that a single LRRK2 mutation causes Parkinson's disease in 5% of individuals with familial disease. Screening for this mutation should be a component of genetic testing for Parkinson's disease.
PMID: 15680455 [PubMed - indexed for MEDLINE]